Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Guizhou Jingfeng Pharmaceutical is a core subsidiary of the Hunan Jingfeng Pharmaceutical Group, a publicly traded Chinese pharmaceutical company specializing in injectable medications. The company focuses on several key therapeutic areas, including cardiovascular health, orthopedics, and ophthalmology, with a portfolio that blends chemical drugs and modernized Traditional Chinese Medicine (TCM). Its flagship products include Sodium Hyaluronate Injection for joint and eye health, as well as TCM injections like Shenmai and Dengzhan Xixin. Guizhou Jingfeng operates multiple GMP-certified production lines and maintains a strong presence in the domestic Chinese market. Despite recent financial restructuring at the group level, the Guizhou entity remains a vital operational unit for the company's commercial strategy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Guizhou Jingfeng Pharmaceutical.